Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.46B |
| 2 |
NVIDIA
NVDA
|
+$1.08B |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$609M |
| 4 |
Moderna
MRNA
|
+$599M |
| 5 |
UBS Group
UBS
|
+$478M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.11B |
| 2 |
Apple
AAPL
|
+$679M |
| 3 |
Palo Alto Networks
PANW
|
+$450M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$428M |
| 5 |
Microsoft
MSFT
|
+$361M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.97% |
| 2 | Financials | 8.75% |
| 3 | Healthcare | 7.15% |
| 4 | Consumer Discretionary | 6.46% |
| 5 | Communication Services | 5.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3126
Liberty Latin America Class A
LILA
$1.64B
| $574K | ﹤0.01% |
72,437
+44,270
| +157% | +$368K |
|
3127
Frontier Group Holdings
ULCC
$1.55B
| $574K | ﹤0.01% |
42,264
+28,034
| +197% | +$429K |
|
3128
BioLife Solutions
BLFS
$1.53B
| $570K | ﹤0.01% |
15,303
-17,626
| -54% | -$756K |
|
|
CMRX
3129
DELISTED
Chimerix, Inc.
CMRX
| $570K | ﹤0.01% |
88,606
+58,325
| +193% | +$350K |
|
|
ASLN
3130
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $570K | ﹤0.01% |
12,724
+8,005
| +170% | +$480K |
|
3131
British American Tobacco
BTI
$131B
| $568K | ﹤0.01% |
15,187
+14,797
| +3,794% | +$525K |
|
3132
Equinor
EQNR
$97.7B
| $568K | ﹤0.01% |
21,568
-2
| -0% | -$53 |
|
3133
Waterstone Financial
WSBF
$370M
| $568K | ﹤0.01% |
25,958
+16,938
| +188% | +$358K |
|
3134
Merchants Bancorp
MBIN
$2.53B
| $565K | ﹤0.01% |
17,928
+11,623
| +184% | +$349K |
|
|
MRSN
3135
DELISTED
Mersana Therapeutics
MRSN
| $561K | ﹤0.01% |
3,605
+2,284
| +173% | +$444K |
|
3136
Precision BioSciences
DTIL
$180M
| $559K | ﹤0.01% |
2,517
+1,269
| +102% | +$354K |
|
3137
Century Casinos
CNTY
$34M
| $558K | ﹤0.01% |
45,776
+21,842
| +91% | +$307K |
|
3138
PUT
Stratasys
SSYS
$679M
| $558K | ﹤0.01% |
22,800
| – | – |
|
3139
Stoke Therapeutics
STOK
$1.8B
| $556K | ﹤0.01% |
23,169
+14,000
| +153% | +$334K |
|
|
AERI
3140
DELISTED
Aerie Pharmaceuticals
AERI
| $553K | ﹤0.01% |
78,815
+35,264
| +81% | +$369K |
|
3141
Rigel Pharmaceuticals
RIGL
$681M
| $550K | ﹤0.01% |
20,739
-14,985
| -42% | -$452K |
|
3142
National Presto Industries
NPK
$870M
| $548K | ﹤0.01% |
6,675
+1,469
| +28% | +$123K |
|
|
BDSI
3143
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $547K | ﹤0.01% |
176,444
+10,392
| +6% | +$35K |
|
|
ZEUS
3144
DELISTED
Olympic Steel
ZEUS
| $544K | ﹤0.01% |
23,181
+4,351
| +23% | +$105K |
|
3145
Greenlight Captial
GLRE
$552M
| $543K | ﹤0.01% |
69,168
+21,087
| +44% | +$155K |
|
3146
Organogenesis Holdings
ORGO
$305M
| $543K | ﹤0.01% |
58,663
+9,766
| +20% | +$104K |
|
3147
Spectrum Brands
SPB
$2.04B
| $542K | ﹤0.01% |
5,334
-3,471
| -39% | -$341K |
|
|
FRBK
3148
DELISTED
Republic First Bancorp Inc
FRBK
| $542K | ﹤0.01% |
145,562
+36,001
| +33% | +$121K |
|
3149
American Public Education
APEI
$890M
| $540K | ﹤0.01% |
24,304
+9,276
| +62% | +$220K |
|
3150
Radiant Logistics
RLGT
$386M
| $540K | ﹤0.01% |
74,099
+31,603
| +74% | +$227K |
|
Similar funds
Barclays's Q4 2021 Portfolio in Review
As of Q4 2021, Barclays held 5,008 positions worth $268B, up 21% from $222B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Barclays deployed $30.5B of net new capital in Q4 2021, opening 209 new positions and adding to 2,223 existing holdings. Its largest new stake was UBS Group: 27,173,428 shares worth $486M.
By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.11B trimmed.
- Barclays's largest Q4 2021 buy was UBS Group: 27,173,428 shares worth $486M.
- Barclays added most to iShares 20+ Year Treasury Bond ETF in Q4 2021, an estimated $1.46B increase.
- Barclays's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.11B.
- Barclays fully exited Vanguard Total International Bond ETF in Q4 2021, selling an estimated $89.8M.
- Barclays's ten largest holdings make up 30% of its $268B portfolio in Q4 2021.
- Barclays opened 209 new positions and closed 867 in Q4 2021.
- Barclays's portfolio value rose 21% quarter-over-quarter to $268B.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.